Clinical use of lentiviral vectors.
Clinical use of lentiviral vectors.
复制标题
DOI:
10.1038/s41375-018-0106-0
复制
发表时间:
2018-07
期刊:
影响因子:
11.4
通讯作者:
O'Doherty U
中科院分区:
文献类型:
--
作者:
Milone MC;O'Doherty U
Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.
登录
查看更多内容
影响因子:
3.2
作者:
Escors, David;Breckpot, Karine
通讯作者:
Breckpot, Karine
DOI:
10.1038/nrmicro3503
发表时间:
2015-08
期刊:
Nature reviews. Microbiology
影响因子:
--
作者:
Campbell EM;Hope TJ
通讯作者:
Hope TJ
影响因子:
17.1
作者:
Cantore, Alessio;Ranzani, Marco;Naldini, Luigi
通讯作者:
Naldini, Luigi
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
4
作者:
Demeulemeester, Jonas;De Rijck, Jan;Gijsbers, Rik;Debyser, Zeger
通讯作者:
Debyser, Zeger